Brugada Syndrome in Pediatric Patients: Risk Stratification and ICD Therapy
Brugada syndrome is an inherited cardiac electrical disorder associated with ventricular fibrillation, polymorphic ventricular tachycardia, syncope, and sudden cardiac death. In children, diagnosis and management are particularly demanding because the electrocardiographic phenotype may be intermittent, fever-dependent, or influenced by age-related changes in autonomic tone and cardiac development.
Risk assessment cannot be reduced to the presence of a Brugada-pattern ECG alone. A child’s symptoms, documented arrhythmias, family history, genetic findings, fever response, ECG evolution, and quality of follow-up all contribute to the clinical picture. Implantable cardioverter-defibrillator (ICD) therapy may prevent fatal arrhythmia in selected patients, but it also carries substantial lifelong consequences.
The most appropriate approach combines careful diagnosis, prevention of triggers, structured surveillance, and individualized discussion with the child and family. Pediatric electrophysiology expertise is essential, particularly when the potential benefit of an ICD must be weighed against inappropriate shocks, lead failure, infection, vascular access limitations, and psychological effects.
Establishing a reliable diagnosis
The diagnostic hallmark is a type 1 Brugada ECG pattern, characterized by coved ST-segment elevation in the right precordial leads, especially V1 and V2. These leads may be positioned in higher intercostal spaces to increase diagnostic sensitivity. A spontaneous type 1 pattern is generally more informative than a pattern revealed only after pharmacological challenge, although interpretation must account for technical quality and clinical context.
Fever can unmask the ECG phenotype and increase arrhythmic risk. Children with unexplained fever should receive prompt temperature management, and an ECG is appropriate when there is a personal or family history suggestive of Brugada syndrome. Sodium-channel blocker challenge requires specialist supervision because it can provoke malignant ventricular arrhythmias, especially in younger patients or those with an already abnormal ECG.
Phenocopies must be considered before assigning a lifelong diagnosis. Myocarditis, electrolyte disturbances, ischemia, medication effects, and technical lead placement can produce Brugada-like patterns. A single transient ECG finding without corroborating clinical or family evidence should not automatically result in an ICD recommendation.
Clinical features that shape risk
A history of documented ventricular fibrillation or sustained ventricular tachycardia is the strongest practical marker of recurrent life-threatening arrhythmia. In a child who has survived cardiac arrest without a reversible explanation, secondary-prevention ICD therapy is usually considered unless the event was clearly caused by another condition.
Unexplained arrhythmic syncope is also important, but the history must be carefully reconstructed. Sudden loss of consciousness without a prodrome, injury, nocturnal agonal breathing, or a compatible ECG raises concern. By contrast, prolonged standing, emotional distress, dehydration, or a typical vasovagal prodrome may point toward a nonarrhythmic cause. Ambulatory monitoring, exercise testing, echocardiography, and occasionally an implantable loop recorder can help resolve uncertainty.
A spontaneous type 1 ECG pattern, family history of sudden death at a young age, and certain genetic findings may increase concern, but none should be interpreted in isolation. SCN5A variants can support the diagnosis when classified as pathogenic or likely pathogenic, yet many detected variants are uncertain or unrelated to the clinical phenotype. Genetic counseling is important before and after testing, with cascade evaluation offered to relatives when appropriate.
Risk may change over time. Some children show a more recognizable phenotype during fever or adolescence, while others remain asymptomatic for years. Regular reassessment should include medication review, updated family history, ECG review, and evaluation of new episodes such as palpitations, nocturnal breathing abnormalities, seizure-like events, or syncope.
Interpreting pediatric-specific risk
Age affects both disease expression and treatment decisions. Brugada syndrome is less commonly expressed in young children than in adult men, but serious events can occur during childhood, particularly with fever or a strong family history. A normal ECG at one visit does not exclude future expression, and repeated testing should be guided by clinical circumstances rather than performed indiscriminately.
Fever management is a central part of pediatric care. Families should know which symptoms require urgent assessment and should seek medical attention for persistent or high fever, especially when the child has a known type 1 pattern or previous arrhythmia. A written emergency plan can include antipyretic use, hydration guidance, avoidance of certain medications, and instructions for contacting the treating team.
Drug avoidance is equally important. Several medications may worsen sodium-channel dysfunction or provoke arrhythmia in susceptible individuals. Families should consult a reliable, specialist-maintained medication list before giving prescription, over-the-counter, or recreational substances. Broader arrhythmia education, including the role of systemic illness and medication exposure, can be supported by resources such as the Journal of Arrhythmia’s discussion of thyroid and atrial fibrillation, although Brugada-specific decisions require dedicated electrophysiology guidance.
Electrophysiological study (EPS) has a limited and debated role in children. Programmed ventricular stimulation may be considered in selected cases, but inducibility does not reliably replace clinical judgment. Invasive testing should be reserved for situations where the result is likely to change management and performed in experienced centers.
When ICD therapy is justified
ICD implantation is generally strongest for secondary prevention after resuscitated ventricular fibrillation or sustained ventricular tachycardia without a reversible cause. It may also be considered for patients with a convincing arrhythmic syncope and a spontaneous type 1 pattern, particularly when other high-risk features are present. The decision is more complex for an asymptomatic child with an abnormal ECG alone, where routine ICD implantation is usually not justified.
An ICD terminates ventricular tachyarrhythmias, but it does not eliminate the underlying substrate. Pediatric patients may live for decades with the device, increasing cumulative exposure to lead revisions, generator replacements, venous obstruction, infection, inappropriate shocks, and psychological distress. Growth, body size, physical activity, and future access for transvenous leads must be incorporated into device selection.
Transvenous systems provide pacing and antitachycardia functions but require venous access and intracardiac leads. Subcutaneous ICDs avoid intravascular leads and may be attractive for selected children, although they do not provide chronic bradycardia pacing or conventional antitachycardia pacing. The child’s rhythm, anatomy, size, expected growth, defibrillation testing considerations, and center experience should guide the choice.
A shared decision-making process should explain both the benefit and the burden of therapy. Families need realistic information about shock likelihood, device alarms, sports participation, wound care, remote monitoring, driving restrictions when relevant, and emergency procedures. Psychological support can help children manage fear of shocks and concerns about appearance or social stigma.
Comparing management options
No single intervention fits every child with a Brugada phenotype. Management should be proportionate to the estimated risk, the certainty of the diagnosis, and the consequences of treatment. Observation with strict fever and medication precautions may be appropriate for an asymptomatic child without major risk markers, while an ICD is generally favored after a documented malignant ventricular arrhythmia.
Quinidine may be considered when recurrent ventricular arrhythmias occur, when an ICD is contraindicated or declined, or when frequent shocks require adjunctive therapy. It requires attention to drug interactions, gastrointestinal effects, thrombocytopenia, and QT prolongation. Catheter ablation is reserved for highly selected patients, such as those with recurrent ventricular fibrillation and identifiable arrhythmogenic substrate, and does not remove the need for careful follow-up.
| Clinical situation | Usual management emphasis | ICD perspective |
|---|---|---|
| Resuscitated ventricular fibrillation or sustained ventricular tachycardia | Secondary prevention, specialist evaluation, trigger control | Generally strong indication if no reversible cause |
| Convincing arrhythmic syncope with spontaneous type 1 ECG | In-depth assessment, monitoring, possible EPS in selected cases | Consider after individualized risk review |
| Asymptomatic type 1 ECG without additional high-risk findings | Education, fever treatment, medication avoidance, surveillance | Usually no routine ICD |
| Fever-induced type 1 pattern without symptoms | Confirm diagnosis and establish an emergency plan | ICD depends on broader clinical profile |
| Recurrent ventricular arrhythmia or ICD shocks | Device review, trigger assessment, antiarrhythmic or ablation options | ICD may remain necessary, with adjunctive therapy |
| Small child or complex venous anatomy | Multidisciplinary device planning and long-term follow-up | System choice must account for growth and lead burden |
Building durable follow-up
Follow-up should be active rather than limited to checking whether the ECG remains abnormal. Visits can review syncope and palpitations, fever episodes, medication exposures, device data, school and sports participation, emotional well-being, and changes in the family history. Remote monitoring is valuable for many ICD recipients, but it complements rather than replaces clinical assessment.
Exercise recommendations should be individualized. Competitive and high-intensity activities may require specialist review, especially in children with prior ventricular arrhythmia or an ICD. Physical activity supports general health and should not be unnecessarily restricted, but families should understand device-specific precautions, the possibility of shocks during exertion, and the need for emergency planning at school and during travel.
Family screening should be organized carefully. First-degree relatives may require ECG assessment, clinical review, and genetic testing when a pathogenic familial variant is known. Children should receive age-appropriate explanations of their condition and participate in decisions as their maturity allows. Adolescents also need confidential counseling about medication use, recreational drugs, sleep deprivation, and future reproductive or occupational considerations.
Research and practice continue to evolve, making high-quality evidence review essential. Clinicians and investigators can consult the Journal of Arrhythmia for contemporary work on inherited arrhythmia syndromes, electrophysiology, ablation, pacing, and implantable devices.
Practical priorities for clinicians and families
- Confirm the ECG phenotype with appropriate lead placement and repeat assessment when fever or clinical symptoms are relevant.
- Separate arrhythmic syncope from vasovagal, neurological, and hemodynamic causes before considering primary-prevention ICD therapy.
- Create a written fever and medication-avoidance plan that is accessible to parents, schools, and emergency clinicians.
- Discuss transvenous and subcutaneous ICD options in the context of growth, anatomy, pacing needs, lead longevity, and the child’s preferences.
- Reassess risk over time, including new symptoms, family events, genetic information, and device-related complications.
Moving from risk assessment to action
For children with suspected or confirmed Brugada syndrome, the safest pathway is coordinated care involving pediatric cardiology, electrophysiology, genetics, emergency medicine, and the family. Decisions should be documented clearly, revisited as the child grows, and based on the strongest available clinical evidence rather than an isolated ECG finding.
Clinicians developing research, reviews, or clinical guidance on pediatric inherited arrhythmias can consult the journal’s author guidelines when preparing work for peer review. Continued publication and careful interpretation of pediatric data are essential to refine risk prediction and reduce avoidable ICD complications.
Early recognition, disciplined fever management, and individualized device decisions can protect children while preserving the greatest possible quality of life. High-risk patients should be referred promptly to an experienced electrophysiology team, and families should receive a clear emergency plan before leaving specialist care.